1
|
Byrne AJ, Bright SA, McKeown JP, O’Brien JE, Twamley B, Fayne D, Williams DC, Meegan MJ. Design, Synthesis and Biochemical Evaluation of Novel Ethanoanthracenes and Related Compounds to Target Burkitt's Lymphoma. Pharmaceuticals (Basel) 2020; 13:ph13010016. [PMID: 31963567 PMCID: PMC7168933 DOI: 10.3390/ph13010016] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Revised: 01/08/2020] [Accepted: 01/10/2020] [Indexed: 12/12/2022] Open
Abstract
Lymphomas (cancers of the lymphatic system) account for 12% of malignant diseases worldwide. Burkitt’s lymphoma (BL) is a rare form of non-Hodgkin’s lymphoma in which the cancer starts in the immune B-cells. We report the synthesis and preliminary studies on the antiproliferative activity of a library of 9,10-dihydro-9,10-ethanoanthracene based compounds structurally related to the antidepressant drug maprotiline against BL cell lines MUTU-1 and DG-75. Structural modifications were achieved by Diels-Alder reaction of the core 9-(2-nitrovinyl)anthracene with number of dienophiles including maleic anhydride, maleimides, acrylonitrile and benzyne. The antiproliferative activity of these compounds was evaluated in BL cell lines EBV− MUTU-1 and EBV+ DG-75 (chemoresistant). The most potent compounds 13j, 15, 16a, 16b, 16c, 16d and 19a displayed IC50 values in the range 0.17–0.38 μM against the BL cell line EBV− MUTU-1 and IC50 values in the range 0.45–0.78 μM against the chemoresistant BL cell line EBV+ DG-75. Compounds 15, 16b and 16c demonstrated potent ROS dependent apoptotic effects on the BL cell lines which were superior to the control drug taxol and showed minimal cytotoxicity to peripheral blood mononuclear cells (PBMCs). The results suggest that this class of compounds merits further investigation as antiproliferative agents for BL.
Collapse
Affiliation(s)
- Andrew J. Byrne
- School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse St, Dublin 2, D02 R590, Ireland; (A.J.B.); (J.P.M.)
| | - Sandra A. Bright
- School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse St, Dublin 2, D02 R590, Ireland; (S.A.B.); (D.F.); (D.C.W.)
| | - James P. McKeown
- School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse St, Dublin 2, D02 R590, Ireland; (A.J.B.); (J.P.M.)
| | - John E. O’Brien
- School of Chemistry, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse St, Dublin 2, D02 R590, Ireland; (J.E.O.); (B.T.)
| | - Brendan Twamley
- School of Chemistry, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse St, Dublin 2, D02 R590, Ireland; (J.E.O.); (B.T.)
| | - Darren Fayne
- School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse St, Dublin 2, D02 R590, Ireland; (S.A.B.); (D.F.); (D.C.W.)
| | - D. Clive Williams
- School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse St, Dublin 2, D02 R590, Ireland; (S.A.B.); (D.F.); (D.C.W.)
| | - Mary J. Meegan
- School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse St, Dublin 2, D02 R590, Ireland; (A.J.B.); (J.P.M.)
- Correspondence: ; Tel.: +353-1-896-2798; Fax: +353-1-8962793
| |
Collapse
|
2
|
Russell S, Rahmani R, Jones AJ, Newson HL, Neilde K, Cotillo I, Rahmani Khajouei M, Ferrins L, Qureishi S, Nguyen N, Martinez-Martinez MS, Weaver DF, Kaiser M, Riley J, Thomas J, De Rycker M, Read KD, Flematti GR, Ryan E, Tanghe S, Rodriguez A, Charman SA, Kessler A, Avery VM, Baell JB, Piggott MJ. Hit-to-Lead Optimization of a Novel Class of Potent, Broad-Spectrum Trypanosomacides. J Med Chem 2016; 59:9686-9720. [DOI: 10.1021/acs.jmedchem.6b00442] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- Stephanie Russell
- School
of Chemistry and Biochemistry, The University of Western Australia, 35 Stirling Highway, Crawley, Perth 6009, Western Australia, Australia
| | - Raphaël Rahmani
- Medicinal
Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Amy J. Jones
- Eskitis
Institute for Drug Discovery, Griffith University, Brisbane Innovation Park, Don Young
Road, Nathan, Queensland 4111, Australia
| | - Harriet L. Newson
- School
of Chemistry and Biochemistry, The University of Western Australia, 35 Stirling Highway, Crawley, Perth 6009, Western Australia, Australia
| | - Kevin Neilde
- Medicinal
Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
- GlaxoSmithKline, 28760 Tres Cantos, Spain
| | | | - Marzieh Rahmani Khajouei
- School
of Chemistry and Biochemistry, The University of Western Australia, 35 Stirling Highway, Crawley, Perth 6009, Western Australia, Australia
| | - Lori Ferrins
- Medicinal
Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Sana Qureishi
- School
of Chemistry and Biochemistry, The University of Western Australia, 35 Stirling Highway, Crawley, Perth 6009, Western Australia, Australia
| | - Nghi Nguyen
- Medicinal
Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | | | - Donald F. Weaver
- Department
of Chemistry, Dalhousie University, Halifax Nova Scotia B3H 4R2, Canada
| | - Marcel Kaiser
- Swiss Tropical and Public Health Institute, Socinstrasse, 4051 Basel, Switzerland
- University of Basel, Petesplatz
1, 4003 Basel, Switzerland
| | - Jennifer Riley
- Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
School of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K
| | - John Thomas
- Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
School of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K
| | - Manu De Rycker
- Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
School of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K
| | - Kevin D. Read
- Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
School of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K
| | - Gavin R. Flematti
- School
of Chemistry and Biochemistry, The University of Western Australia, 35 Stirling Highway, Crawley, Perth 6009, Western Australia, Australia
| | - Eileen Ryan
- Centre
for Drug Candidate Optimisation, Monash University, Parkville, Victoria 3052, Australia
| | - Scott Tanghe
- Anti-Infectives
Screening Core, New York University School of Medicine, New York, New York 10010, United States
| | - Ana Rodriguez
- Anti-Infectives
Screening Core, New York University School of Medicine, New York, New York 10010, United States
| | - Susan A. Charman
- Medicinal
Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
- Centre
for Drug Candidate Optimisation, Monash University, Parkville, Victoria 3052, Australia
| | | | - Vicky M. Avery
- Eskitis
Institute for Drug Discovery, Griffith University, Brisbane Innovation Park, Don Young
Road, Nathan, Queensland 4111, Australia
| | - Jonathan B. Baell
- Medicinal
Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Matthew J. Piggott
- School
of Chemistry and Biochemistry, The University of Western Australia, 35 Stirling Highway, Crawley, Perth 6009, Western Australia, Australia
| |
Collapse
|
3
|
Newson HL, Wild DA, Yeung SY, Skelton BW, Flematti GR, Allan JE, Piggott MJ. Access to 1,2,3,4-Tetraoxygenated Benzenes via a Double Baeyer–Villiger Reaction of Quinizarin Dimethyl Ether: Application to the Synthesis of Bioactive Natural Products from Antrodia camphorata. J Org Chem 2016; 81:3127-35. [DOI: 10.1021/acs.joc.5b02861] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Harriet L. Newson
- School of Chemistry and Biochemistry, ‡Centre for Microscopy, Characterisation
and Analysis, §School of Medicine and Pharmacology, The University of Western Australia, Perth, WA 6009, Australia
| | - Duncan A. Wild
- School of Chemistry and Biochemistry, ‡Centre for Microscopy, Characterisation
and Analysis, §School of Medicine and Pharmacology, The University of Western Australia, Perth, WA 6009, Australia
| | - Sing Yee Yeung
- School of Chemistry and Biochemistry, ‡Centre for Microscopy, Characterisation
and Analysis, §School of Medicine and Pharmacology, The University of Western Australia, Perth, WA 6009, Australia
| | - Brian W. Skelton
- School of Chemistry and Biochemistry, ‡Centre for Microscopy, Characterisation
and Analysis, §School of Medicine and Pharmacology, The University of Western Australia, Perth, WA 6009, Australia
| | - Gavin R. Flematti
- School of Chemistry and Biochemistry, ‡Centre for Microscopy, Characterisation
and Analysis, §School of Medicine and Pharmacology, The University of Western Australia, Perth, WA 6009, Australia
| | - Jane E. Allan
- School of Chemistry and Biochemistry, ‡Centre for Microscopy, Characterisation
and Analysis, §School of Medicine and Pharmacology, The University of Western Australia, Perth, WA 6009, Australia
| | - Matthew J. Piggott
- School of Chemistry and Biochemistry, ‡Centre for Microscopy, Characterisation
and Analysis, §School of Medicine and Pharmacology, The University of Western Australia, Perth, WA 6009, Australia
| |
Collapse
|
4
|
Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM. UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances l-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. Neuropharmacology 2014; 82:76-87. [DOI: 10.1016/j.neuropharm.2014.01.012] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2013] [Revised: 11/29/2013] [Accepted: 01/07/2014] [Indexed: 11/16/2022]
|
5
|
Punch KA, Piggott MJ. Total synthesis of monosporascone and dihydromonosporascone. Org Biomol Chem 2014; 12:2801-10. [DOI: 10.1039/c4ob00331d] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The first synthesis of monosporascone has been achieved in five steps and 57% overall yield.
Collapse
Affiliation(s)
- Kathryn A. Punch
- School of Chemistry and Biochemistry
- The University of Western Australia
- Perth, Australia
| | - Matthew J. Piggott
- School of Chemistry and Biochemistry
- The University of Western Australia
- Perth, Australia
| |
Collapse
|
6
|
Johnston TH, Millar Z, Huot P, Wagg K, Thiele S, Salomonczyk D, Yong‐Kee CJ, Gandy MN, McIldowie M, Lewis KD, Gomez‐Ramirez J, Lee J, Fox SH, Martin‐Iverson M, Nash JE, Piggott MJ, Brotchie JM. A novel MDMA analogue, UWA‐101, that lacks psychoactivity and cytotoxicity, enhances
l
‐DOPA benefit in parkinsonian primates. FASEB J 2012; 26:2154-63. [DOI: 10.1096/fj.11-195016] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Affiliation(s)
- Tom H. Johnston
- Toronto Western Research InstituteToronto Western HospitalUniversity Health NetworkTorontoOntarioCanada
| | - Zak Millar
- School of Medicine and PharmacologyThe University of Western AustraliaPerthAustralia
| | - Philippe Huot
- Toronto Western Research InstituteToronto Western HospitalUniversity Health NetworkTorontoOntarioCanada
| | - Keith Wagg
- Department of ChemistryThe Australian National UniversityCanberraAustralia
| | - Sherri Thiele
- Department of Biological SciencesUniversity of Toronto at ScarboroughTorontoOntarioCanada
| | - Danielle Salomonczyk
- Department of Biological SciencesUniversity of Toronto at ScarboroughTorontoOntarioCanada
| | | | - Michael N. Gandy
- School of Biomedical, Biomolecular, and Chemical SciencesThe University of Western AustraliaPerthAustralia
| | - Matthew McIldowie
- School of Biomedical, Biomolecular, and Chemical SciencesThe University of Western AustraliaPerthAustralia
| | - Katie D. Lewis
- School of Biomedical, Biomolecular, and Chemical SciencesThe University of Western AustraliaPerthAustralia
| | - Jordi Gomez‐Ramirez
- Toronto Western Research InstituteToronto Western HospitalUniversity Health NetworkTorontoOntarioCanada
| | - Joohyung Lee
- Toronto Western Research InstituteToronto Western HospitalUniversity Health NetworkTorontoOntarioCanada
| | - Susan H. Fox
- Movement Disorders ClinicToronto Western HospitalUniversity Health NetworkTorontoOntarioCanada
| | - Mathew Martin‐Iverson
- School of Medicine and PharmacologyThe University of Western AustraliaPerthAustralia
| | - Joanne E. Nash
- Department of Biological SciencesUniversity of Toronto at ScarboroughTorontoOntarioCanada
| | - Matthew J. Piggott
- School of Biomedical, Biomolecular, and Chemical SciencesThe University of Western AustraliaPerthAustralia
| | - Jonathan M. Brotchie
- Toronto Western Research InstituteToronto Western HospitalUniversity Health NetworkTorontoOntarioCanada
| |
Collapse
|
7
|
Wasik AM, Millan MJ, Scanlan T, Barnes NM, Gordon J. Evidence for functional trace amine associated receptor-1 in normal and malignant B cells. Leuk Res 2011; 36:245-9. [PMID: 22036195 DOI: 10.1016/j.leukres.2011.10.002] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2011] [Revised: 10/05/2011] [Accepted: 10/07/2011] [Indexed: 11/15/2022]
Abstract
Following the observation that dopaminergic components are present in normal and malignant B cells, we now provide evidence that they additionally express the functionally related trace amine-associated receptor-1 (TAAR1). Immunodetectable TAAR1 was found in lines derived from a broad range of B-cell malignancy; and in tonsillar B cells, particularly when activated. L3055 Burkitt's lymphoma cells were shown to respond to prototypical TAAR1 agonists in cytotoxicity assays with features of apoptotic death evident; normal B cells were somewhat less sensitive to the agonists. These data raise the possibility that TAAR1 may have therapeutic relevance to leukemia, lymphoma, and wider B-cell pathologies.
Collapse
Affiliation(s)
- Agata M Wasik
- School of Immunity & Infection, The Medical School, Birmingham, UK
| | | | | | | | | |
Collapse
|
8
|
Wasik AM, Gandy MN, McIldowie M, Holder MJ, Chamba A, Challa A, Lewis KD, Young SP, Scheel-Toellner D, Dyer MJ, Barnes NM, Piggott MJ, Gordon J. Enhancing the anti-lymphoma potential of 3,4-methylenedioxymethamphetamine ('ecstasy') through iterative chemical redesign: mechanisms and pathways to cell death. Invest New Drugs 2011; 30:1471-83. [PMID: 21850491 DOI: 10.1007/s10637-011-9730-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2011] [Accepted: 08/01/2011] [Indexed: 11/29/2022]
Abstract
While 3,4-methylenedioxymethamphetamine (MDMA/'ecstasy') is cytostatic towards lymphoma cells in vitro, the concentrations required militate against its translation directly to a therapeutic in vivo. The possibility of 'redesigning the designer drug', separating desired anti-lymphoma activity from unwanted psychoactivity and neurotoxicity, was therefore mooted. From an initial analysis of MDMA analogues synthesized with a modified α-substituent, it was found that incorporating a phenyl group increased potency against sensitive, Bcl-2-deplete, Burkitt's lymphoma (BL) cells 10-fold relative to MDMA. From this lead, related analogs were synthesized with the 'best' compounds (containing 1- and 2-naphthyl and para-biphenyl substituents) some 100-fold more potent than MDMA versus the BL target. When assessed against derived lines from a diversity of B-cell tumors MDMA analogues were seen to impact the broad spectrum of malignancy. Expressing a BCL2 transgene in BL cells afforded only scant protection against the analogues and across the malignancies no significant correlation between constitutive Bcl-2 levels and sensitivity to compounds was observed. Bcl-2-deplete cells displayed hallmarks of apoptotic death in response to the analogues while BCL2 overexpressing equivalents died in a caspase-3-independent manner. Despite lymphoma cells expressing monoamine transporters, their pharmacological blockade failed to reverse the anti-lymphoma actions of the analogues studied. Neither did reactive oxygen species account for ensuing cell death. Enhanced cytotoxic performance did however track with predicted lipophilicity amongst the designed compounds. In conclusion, MDMA analogues have been discovered with enhanced cytotoxic efficacy against lymphoma subtypes amongst which high-level Bcl-2--often a barrier to drug performance for this indication--fails to protect.
Collapse
Affiliation(s)
- Agata M Wasik
- School of Immunity & Infection, The Medical School, Birmingham, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|